ArticleJournal of experimental & clinical cancer research : CR2024

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.

Jangsoon Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.